Abstract
Current generation coronary drug‐eluting stents (DES) used to treat restenosis are associated with unintended complications including potentially fatal late‐term thrombosis and hypersensitivity reactions. This provides a platform for novel engineered device therapies that exhibit increased biocompatibility and promote vascular healing after angioplasty. Resveratrol and quercetin have antimitogenic actions on vascular smooth muscle cells (VSMC) and inhibit both platelet and inflammatory cell activation. Our aim was to develop a stent coating that releases these drugs within a therapeutic range and provides an extended release profile to inhibit cascades responsible for restenosis and thrombosis. Stainless steel flats were coated with arborescent polyisobutylene‐polystyrene polymer (arbIBS) applied using the novel NanoElectrospray(TM) process. To determine DES‐mediated effects, assays were conducted on flats incubated in transwells in the presence of vascular cells. These included measures of cell viability, platelet activation, and cell proliferation. Results from this study indicate that arbIBS exhibits no cytotoxicity, and that the nanoparticles release resveratrol and quercetin at the therapeutic level, reducing platelet activation and VSMC proliferation. Ongoing experiments are aimed at introducing these DES into an animal model of angioplasty for further evaluation.Grant Funding SourceR01‐HL082472
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
